Madrigal Pharmaceuticals (MDGL) News Today

$339.40 -11.63 (-3.31%)

As of 02:22 PM Eastern

Compare

Source

Time Period

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

February 21 at 8:00 AM | globenewswire.com

Head-To-Head Contrast: Madrigal Pharmaceuticals (NASDAQ:MDGL) versus Ovid Therapeutics (NASDAQ:OVID)

February 21 at 2:27 AM | americanbankingnews.com

14,760 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 14,760 shares of the biopharmaceutical company's stock, valued at ap

February 19 at 5:14 AM | marketbeat.com

Madrigal Pharmaceuticals (MDGL) Projected to Post Earnings on Wednesday

Madrigal Pharmaceuticals (NASDAQ:MDGL) will be releasing earnings before the market opens on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665336)

February 19 at 3:38 AM | marketbeat.com

Madrigal Pharmaceuticals price target raised to $400 from $336 at Piper Sandler

February 14, 2025 | markets.businessinsider.com

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler

February 14, 2025 | markets.businessinsider.com

Fiera Capital Corp Sells 4,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Fiera Capital Corp decreased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 4.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,422 shares of the biopharmaceutical company's s

February 14, 2025 | marketbeat.com

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Evercore ISI

February 13, 2025 | markets.businessinsider.com

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

February 12, 2025 | globenewswire.com

What is Leerink Partnrs' Forecast for MDGL FY2024 Earnings?

February 12, 2025 | americanbankingnews.com

Leerink Partnrs Issues Optimistic Estimate for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2024 earnings estimates for Madrigal Pharmaceuticals in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical compan

February 10, 2025 | marketbeat.com

Newbridge Financial Services Group Inc. Invests $1.30 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Newbridge Financial Services Group Inc. acquired a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,203 shares of the bi

February 9, 2025 | marketbeat.com

FY2026 EPS Estimates for MDGL Cut by Leerink Partnrs

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities researchers at Leerink Partnrs cut their FY2026 EPS estimates for shares of Madrigal Pharmaceuticals in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the bio

February 7, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Sells 6,643 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Mirae Asset Global Investments Co. Ltd. decreased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 8.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 70,179 shares of the biopharmaceutical company's stock after s

February 6, 2025 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Position Decreased by Rheos Capital Works Inc.

Rheos Capital Works Inc. reduced its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 43.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,215 shares of the biopharmaceut

February 3, 2025 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating an

February 1, 2025 | marketbeat.com

David Lebowitz’s Buy Recommendation for Madrigal Pharmaceuticals Amid Positive Outlook and Promising Future Prospects

January 29, 2025 | markets.businessinsider.com

B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)

January 28, 2025 | markets.businessinsider.com

Positive Outlook for Madrigal Pharmaceuticals Driven by Rezdiffra’s Potential and Market Opportunity

January 28, 2025 | markets.businessinsider.com

Promising Outlook for Madrigal Pharmaceuticals Amidst Positive Data and Market Potential

January 28, 2025 | markets.businessinsider.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 103 Shares

January 28, 2025 | insidertrades.com

Madrigal dip on Akero data a buying opportunity, says Evercore ISI

January 27, 2025 | markets.businessinsider.com

Madrigal Pharmaceuticals executive sells shares worth $34,529

January 27, 2025 | msn.com

Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock

January 27, 2025 | msn.com

Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 103 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 103 shares of the business's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $34,529.72. Following the transaction, the vice president now directly owns 4,955 shares of the company's stock, valued at approximately $1,661,114.20. This represents a 2.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

January 27, 2025 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) insider Carole Huntsman sold 347 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $116,328.28. Following the transaction, the insider now owns 10,438 shares in the company, valued at approximately $3,499,235.12. This trade represents a 3.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

January 27, 2025 | marketbeat.com

Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CMO Rebecca Taub sold 648 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $217,235.52. Following the completion of the sale, the chief marketing officer now directly owns 456,662 shares in the company, valued at approximately $153,091,368.88. The trade was a 0.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

January 27, 2025 | marketbeat.com

Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells 1,584 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CEO William John Sibold sold 1,584 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $531,020.16. Following the transaction, the chief executive officer now owns 54,303 shares in the company, valued at $18,204,537.72. This trade represents a 2.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

January 27, 2025 | marketbeat.com

Equities Analysts Offer Predictions for MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the bio

January 23, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Madrigal Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company wil

January 22, 2025 | marketbeat.com

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

January 19, 2025 | seekingalpha.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Sells $75,734.57 in Stock

January 18, 2025 | insidertrades.com

Shannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) General Counsel Shannon T. Kelley sold 277 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $75,734.57. Following the transaction, the general counsel now owns 7,705 shares of the company's stock, valued at $2,106,624.05. This trade represents a 3.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.